Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.59 |
| ▸ | IL1RN | P18510 | 3/20 | 0.59 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8100239 | 0.88 | ERAP2 (0.63) | ERAP2IL1RNERAP1EGLN1VEGFA | |
| SCHEMBL8102437 | 0.85 | ERAP2 (0.60) | ERAP2IL1RNERAP1KDM4E | |
| SCHEMBL8102285 | 0.84 | ERAP2 (0.54) | ERAP2IL1RNERAP1BRD4EGLN1 | |
| SCHEMBL9513063 | 0.83 | ERAP2 (0.64) | ERAP2IL1RNERAP1EGLN1VEGFA | |
| SCHEMBL9511617 | 0.83 | ERAP2 (0.64) | ERAP2IL1RNERAP1EGLN1VEGFA | |
| SCHEMBL10966257 | 0.82 | ERAP2 (0.63) | ERAP2IL1RNERAP1EGLN1VEGFA | |
| SCHEMBL9385864 | 0.81 | ERAP2 (0.62) | ERAP2IL1RNERAP1EGLN1VEGFA | |
| SCHEMBL13036960 | 0.78 | EGLN1 (0.51) | ERAP2IL1RNERAP1EGLN1VEGFA | |
| SCHEMBL8102665 | 0.78 | KDM4E (0.50) | ERAP2IL1RNERAP1EGLN1VEGFA | |
| SCHEMBL8268683 | 0.76 | ERAP2 (0.78) | ERAP2IL1RNERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE36831-E | TREATMENT OF IRON DEFICIENCY ANEMIA | BRITISH TECHNOLOGY GROUP LTD. (GB) | 2000-08-22 | — | — | US | disclosed |
| US-RE35948-E | TREATING TOXIC METAL CONCENTRATION BY ADMINISTERING N-SUBSTITUTED 3-HYDROXYPYRID-2-ONE OR 3-HYDROXYPYRID-4-ONE | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1998-11-03 | — | — | US | disclosed |
| EP-0305646-A2 | 3-Hydroxypyrid-4-ones and pharmaceutical compositions | BTG INTERNATIONAL LIMITED (GB) | 1989-03-08 | — | — | EP | disclosed |
| EP-0120670-B1 | IRON III COMPLEXES OF HYDROXYPYRIDONES, AND THEIR PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1988-12-21 | — | — | EP | disclosed |
| US-4650793-A | NITROGEN-SUBSTITUTED | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-03-17 | — | — | US | disclosed |
| US-4585780-A | CHELATION OF HEAVY METALS IN BLOOD | NATIONAL RESEARCH DEVELOPMENT CORP. (GB) | 1986-04-29 | — | — | US | disclosed |
| EP-0120669-A2 | Hydroxypyridones, and their pharmaceutical compositions | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-10-03 | — | — | EP | disclosed |
| EP-0120670-A1 | Iron III complexes of hydroxypyridones, and their pharmaceutical compositions | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-10-03 | — | — | EP | disclosed |